Literature DB >> 182897

Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies.

J M Lindstrom, A G Engel, M E Seybold, V A Lennon, E H Lambert.   

Abstract

Passive transfer of experimental autoimmune myasthenia gravis (EAMG) was achieved using the gamma globulin fraction and purified IgG from sera of rats immunized with Electrophus electricus (eel) acetylcholine receptor (AChR). This demonstrates the critical role of anti-AChR antibodies in impairing neuromuscular transmission in EAMG. Passive transfer of anti-AChR antibodies from rats with chronic EAMG induced signs of the acute phase of EAMG in normal recipient rats, including invasion of the motor end-plate region by mononuclear inflammatory cells. Clinical, eletrophysiological, histological, and biochemical signs of acute EAMG were observed by 24 h after antibody transfer. Recipient rats developed profound weakness and fatigability, and the posture characteristic of EAMG. Striking weight loss was attributable to dehydration. Recipient rats showed large decreases in amplitude of muscle responses to motor nerve stimulation, and repetitive nerve stimulation induced characteristic decrementing responses. End-plate potentials were not detectable in many muscle fibers, and the amplitudes of miniature end-plate potentials were reduced in the others. Passively transferred EAMG more severely affected the forearm muscles than diaphragm muscles, though neuromuscular transmission was impaired and curare sensitivity was increased in both muscles. Some AChR extracted from the muscles of rats with passively transferred EAMG was found to be complexed with antibody, and the total yield of AChR per rat was decreased. The quantitative decrease in AChR approximately paralleled in time the course of clinical and electrophysiological signs. The amount of AChR increased to normal levels and beyond at the time neuromuscular transmission was improving. The excess of AChR extractable from muscle as the serum antibody level decreased probably represented extrajunctional receptors formed in response to functional denervation caused by phagocytosis of the postsynaptic membrane by macrophages. The amount of antibody required to passively transfer EAMG was less than required to bind all AChR molecules in a rat's musculature. The effectiveness of samll amounts of antibody was probably amplified by the activation of complement and by the destruction of large areas of postsynaptic membrane by phagocytic cells. A self-sustaining autoimmune response to AChR was not provoked in animals with passively transferred EAMG.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 182897      PMCID: PMC2190413          DOI: 10.1084/jem.144.3.739

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  17 in total

1.  Experimental autoimmune myasthenia: clinical, neurophysiologic, and pharmacologic aspects.

Authors:  M E Seybold; E H Lambert; V A Lennon; J M Lindstrom
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

2.  The motor end plate in myasthenia gravis and in experimental autoimmune myasthenia gravis. A quantitative ultrastructural study.

Authors:  A G Engel; M Tsujihata; J M Lindstrom; V A Lennon
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

3.  Synthesis of acetylcholine receptor by denervated rat diaphragm muscle.

Authors:  J P Brockes; Z W Hall
Journal:  Proc Natl Acad Sci U S A       Date:  1975-04       Impact factor: 11.205

4.  Experimental autoimmune myasthenia gravis: cellular and humoral immune responses.

Authors:  V A Lennon; J M Lindstrom; M E Seybold
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

5.  Myasthenia gravis: passive transfer from man to mouse.

Authors:  K V Toyka; D B Brachman; A Pestronk; I Kao
Journal:  Science       Date:  1975-10-24       Impact factor: 47.728

6.  Experimental autoimmune myasthenia gravis and myasthenia gravis: biochemical and immunochemical aspects.

Authors:  J M Lindstrom; V A Lennon; M E Seybold; S Whittingham
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

7.  End-plate potentials in experimental autoimmune myasthenia gravis in rats.

Authors:  E H Lambert; J M Lindstrom; V A Lennon
Journal:  Ann N Y Acad Sci       Date:  1976       Impact factor: 5.691

8.  Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs.

Authors:  V A Lennon; J M Lindstrom; M E Seybold
Journal:  J Exp Med       Date:  1975-06-01       Impact factor: 14.307

9.  Selective expression of H-2 (i-region) loci controlling determinants on helper and suppressor T lymphocytes.

Authors:  K Okumura; L A Herzenberg; D B Murphy; H O McDevitt; L A Herzenberg
Journal:  J Exp Med       Date:  1976-09-01       Impact factor: 14.307

10.  Passive transfer of experimental autoimmune myasthenia by lymph node cells in inbred guinea pigs.

Authors:  R Tarrab-Hazdi; A Aharonov; O Abramsky; I Yaar; S Fuchs
Journal:  J Exp Med       Date:  1975-09-01       Impact factor: 14.307

View more
  50 in total

1.  Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors.

Authors:  Jie Luo; Jon Lindstrom
Journal:  Autoimmunity       Date:  2011-10-21       Impact factor: 2.815

2.  Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing.

Authors:  Jason A Vander Heiden; Panos Stathopoulos; Julian Q Zhou; Luan Chen; Tamara J Gilbert; Christopher R Bolen; Richard J Barohn; Mazen M Dimachkie; Emma Ciafaloni; Teresa J Broering; Francois Vigneault; Richard J Nowak; Steven H Kleinstein; Kevin C O'Connor
Journal:  J Immunol       Date:  2017-01-13       Impact factor: 5.422

Review 3.  Immunopathologic events at the endplate in myasthenia gravis.

Authors:  T Ashizawa; S H Appel
Journal:  Springer Semin Immunopathol       Date:  1985

4.  Phenotypic and functional characterization of T cells from patients with myasthenia gravis.

Authors:  F Mokhtarian; M Pino; W Ofosu-Appiah; D Grob
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

Review 5.  Myasthenia gravis: an autoimmune response against the acetylcholine receptor.

Authors:  Y M Graus; M H De Baets
Journal:  Immunol Res       Date:  1993       Impact factor: 2.829

Review 6.  The main immunogenic region (MIR) of the nicotinic acetylcholine receptor and the anti-MIR antibodies.

Authors:  S J Tzartos; M T Cung; P Demange; H Loutrari; A Mamalaki; M Marraud; I Papadouli; C Sakarellos; V Tsikaris
Journal:  Mol Neurobiol       Date:  1991       Impact factor: 5.590

Review 7.  Myasthenia gravis as a prototype autoimmune receptor disease.

Authors:  A C Hoedemaekers; P J van Breda Vriesman; M H De Baets
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

8.  Myasthenia gravis: further electrophysiological and ultrastructural analysis of transmission failure in the mouse passive transfer model.

Authors:  K V Toyka; K L Birnberger; A P Anzil; C Schlegel; U Besinger; A Struppler
Journal:  J Neurol Neurosurg Psychiatry       Date:  1978-08       Impact factor: 10.154

Review 9.  Myasthenia gravis--current concepts.

Authors:  C Herrmann; J M Lindstrom; J C Keesey; D G Mulder
Journal:  West J Med       Date:  1985-06

10.  Subpopulations of T lymphocytes in myasthenia gravis patients.

Authors:  M Piantelli; L Lauriola; A Carbone; A Evoli; P Tonali; P Musiani
Journal:  Clin Exp Immunol       Date:  1979-04       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.